Credit Suisse analyst Alethia Young raised her price target for Puma Technologies earlier today to $136 from $118 after meeting with management at ESMO. The analyst would not expect an official communication that the launch is beginning in September, but notes that Nerlynx is available now and the sales force is actively educating on the product. The company decided to soft launch in July because doctors were inquiring about the drug and so far, have gotten no rejections from the large insurance companies, she adds. Early next year, Young expects Puma will hear about potential approval in Europe. The analyst reiterates an Outperform rating on the shares.